At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

In today’s health headlines, signs that sexually transmitted infections are declining. Could standing desks not be a great ...

This study links rare genetic variants to type 2 diabetes risk, emphasizing their role in monogenic diabetes and potential ...

On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Organic whole and baby carrots have been recalled nationwide due to an E. coli outbreak that has killed at least one person, ...

The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...